Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
161Tb-NYM032
- Development stage
- Phase 2
- Lead developer
- Norroy Bioscience
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
161Tb-NYM032 is an investigational radioligand therapy developed by Zhengguo Chen for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The compound consists of a small molecule ligand, NYM032, which specifically targets the prostate-specific membrane antigen (PSMA) expressed on the surface of prostate cancer cells. It is labeled with terbium-161 (161Tb), a theranostic radionuclide that emits both beta particles and Auger electrons. The inclusion of Auger electrons, which have high linear energy transfer and a very short range, potentially provides superior efficacy against micrometastatic disease and single cancer cells compared to traditional lutetium-177-based therapies. The drug is currently being evaluated in a Phase 1/2 clinical trial to assess its safety, tolerability, and preliminary anti-tumor activity.
- Other names
- Terbium-161 NYM032Terbium161 NYM032Terbium 161 NYM032
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 161Tb-NYM032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 161Tb-NYM032.